Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Programme Assessing Safety and Efficacy of Nivolumab in Italian Patients with Metastatic Renal Cell Carcinoma in a Real World Setting

Trial Profile

Expanded Access Programme Assessing Safety and Efficacy of Nivolumab in Italian Patients with Metastatic Renal Cell Carcinoma in a Real World Setting

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 29 Jun 2018 Results published in the BJU International
    • 12 Sep 2017 Results (n=195) assessing the feasibility of nivolumab in the elderly and very elderly patients, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results (n=346) assessing the prognostic impact of inflammatory indexes on clinical outcomes in patients with metastatic renal cell cancer treated with nivolumab, presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top